ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 860.34Cr 747.89Cr 696.12Cr 639.13Cr 1.21TCr 82TCr 1.23TCr 8.21TCr 3.22TCr 41TCr 3.23TCr 3.16TCr 1,37100Cr | P/E 2026 * |
-14.4x | P/E 2027 * | -28.1x |
|---|---|---|---|---|---|
| Enterprise Value | 820.78Cr 713.5Cr 664.12Cr 609.74Cr 1.15TCr 78TCr 1.17TCr 7.83TCr 3.07TCr 39TCr 3.08TCr 3.01TCr 1,30800Cr | EV / Sales 2026 * |
8.86x | EV / Sales 2027 * | 5.96x |
| Free-Float |
99.09% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Director/Board Member | 73 | 01/05/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 25/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 860.34Cr | |
| -1.40% | +2.59% | -1.71% | +11.28% | 4.85TCr | |
| -2.41% | -0.90% | +403.17% | +614.40% | 3.99TCr | |
| -1.16% | +12.96% | +26.45% | +5.03% | 3.87TCr | |
| -1.88% | -3.03% | +4.94% | +47.52% | 3.51TCr | |
| -1.74% | +5.12% | +9.58% | +46.02% | 2.98TCr | |
| -2.85% | -3.92% | - | - | 1.61TCr | |
| -0.21% | -4.04% | +35.09% | +127.95% | 1.61TCr | |
| -0.64% | +2.65% | +1.25% | +8.92% | 1.36TCr | |
| -1.19% | -1.32% | -3.32% | -34.94% | 1.26TCr | |
| Average | -1.22% | +1.05% | +59.43% | +103.27% | 2.78TCr | |
| Weighted average by Cap. | -1.50% | +2.03% | +76.87% | +128.10% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 93Cr 81Cr 75Cr 69Cr 129.99Cr 8.85TCr 132Cr 883.75Cr 346.84Cr 4.4TCr 347.99Cr 340.35Cr 15TCr | 140.38Cr 122.03Cr 113.59Cr 104.29Cr 196.94Cr 13TCr 199.99Cr 1.34TCr 525.47Cr 6.67TCr 527.21Cr 515.63Cr 22TCr |
| Net income | -60Cr -53Cr -49Cr -45Cr -85Cr -5.77TCr -86Cr -576.37Cr -226.21Cr -2.87TCr -226.96Cr -221.97Cr -9.63TCr | -36Cr -31Cr -29Cr -26Cr -50Cr -3.4TCr -51Cr -339.9Cr -133.4Cr -1.69TCr -133.84Cr -130.9Cr -5.68TCr |
| Net Debt | -40Cr -34Cr -32Cr -29Cr -55Cr -3.78TCr -56Cr -377.26Cr -148.06Cr -1.88TCr -148.55Cr -145.29Cr -6.3TCr | -24Cr -21Cr -19Cr -18Cr -34Cr -2.3TCr -34Cr -229.54Cr -90Cr -1.14TCr -90Cr -88Cr -3.84TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
